Transcend also saw significant improvements on secondary endpoints that assessed the rate of response, remission and loss of ...
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...
Cologuard is getting an upgrade after 10 years on the market, as Exact Sciences starts to roll out the new version of its ...
Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...
Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests ...
Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be used to treat obesity and metabolic diseases ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
The FDA has cleared its first completely at-home sexual health test for women, available over-the-counter to screen for ...
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
The federal government is cutting 3,500 full-time FDA employees and 1,200 NIH workers as part of an overarching move designed ...
CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback